News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating
According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK) has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK.M...
Reset
Send
The window will close in 5 seconds
<Research>UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating
Close
Recommend
7
Positive
6
Negative
4
 
SHORT SELL
 
STOCK INFO

According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK)  +0.750 (+2.836%)    Short selling $41.24M; Ratio 18.679%   has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK.

Meanwhile, HANSOH PHARMA's Hengmeida, which is used for the treatment of candidiasis, has been granted a drug registration certificate by China's National Medical Products Administration. The company's other product development projects are also progressing smoothly.

Related NewsNomura Lifts HANSOH PHARMA's TP to HKD25.64 on Product Licensing
UOB Kay Hian kept a Buy rating on HANSOH PHARMA, with a target price raised to HKD40 from HKD29.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.